Indication: Multiple Myeloma
A Phase 1b, Open-Label Study of Eftozanermin Alfa (ABBV-621) in Combination with Bortezomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Sub-indication: Hematological Malignancies
Study Type: Drug Study
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Sponsor: AbbVie
Email for more information: Heme-NCIResearch@nortonhealthcare.org